3D Medicines (HKSE:01244) Growth Rank : 0 (As of Jun. 05, 2024)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Growth Rank?

3D Medicines has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

3D Medicines Growth Rank Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines